What is the systemic bioavailability of cannabis-based topical lotions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Systemic Bioavailability of Cannabis Topical Lotions

Cannabis-based topical lotions have minimal to negligible systemic bioavailability, with cannabinoids either undetectable or present at extremely low plasma concentrations that are unlikely to produce systemic therapeutic effects.

Evidence from Human Studies

The available evidence consistently demonstrates that topical cannabis formulations result in very limited systemic absorption:

Direct Topical Application Studies

A 2026 crossover pharmacokinetic study directly compared oral versus topical administration of a natural hemp extract-based cosmetic product 1. Following topical application, CBD concentrations were frequently below the limit of quantification (BLQ), and when detectable, remained extremely low with an AUC0-24 of only 19 h·ng/mL compared to 281 h·ng/mL for oral administration. The time to maximum concentration (Tmax) was delayed to 24 hours topically versus 3 hours orally. Critically, THC and its metabolites (including 7-OH-CBD and COOH-THC) were completely unquantifiable after topical use, and urine tests for COOH-THC were negative in all participants using the topical route 1.

Transdermal vs. True Topical Delivery

It's essential to distinguish between transdermal systems (designed for systemic absorption) and topical lotions (intended for local effects):

  • A 2023 study of a specialized transdermal delivery system achieved measurable systemic levels with AUC0-12h of 3329.8 pg/mL/h for CBD and 2093.4 pg/mL/h for THC 2. However, this required a novel penetration-enhancing delivery technology specifically engineered for transdermal absorption.

  • Earlier research (2010) in guinea pigs showed transdermal gel application achieved steady-state plasma concentrations of only 6.3 ± 2.1 ng/mL, requiring 15.5 hours to reach steady state 3. Even with permeation enhancers, concentrations increased only 3.7-fold.

Clinical Context from Guidelines

The 2024 ASCO guideline on cannabis and cannabinoids provides important pharmacokinetic context 4:

  • Oral bioavailability of THC is only 4-12% due to extensive first-pass metabolism
  • Inhaled THC bioavailability is 10-35%
  • Cannabinoids are highly lipophilic and accumulate in adipose tissue
  • The guideline does not discuss topical formulations, reflecting the lack of evidence for systemic therapeutic effects via this route

Key Clinical Implications

For Systemic Therapeutic Effects

Standard topical cannabis lotions should NOT be relied upon for systemic therapeutic benefits such as:

  • Pain management beyond local application sites
  • Chemotherapy-induced nausea and vomiting
  • Appetite stimulation
  • Systemic anti-inflammatory effects

For Local Effects

Topical formulations may provide localized effects through:

  • Direct interaction with peripheral cannabinoid receptors in skin
  • Local anti-inflammatory activity
  • Potential benefits for dermatological conditions 5

Drug Testing Considerations

A significant practical advantage: topical cannabis lotions do not produce positive urine drug tests for THC metabolites 1, unlike oral or inhaled routes. This is clinically relevant for patients subject to workplace or legal drug screening.

Common Pitfalls to Avoid

  1. Do not assume topical = transdermal: Most commercial cannabis lotions lack the specialized delivery technology required for meaningful systemic absorption 2

  2. Patient expectations: Counsel patients that topical lotions work locally, not systemically. If systemic effects are desired, alternative routes (oral, sublingual, inhaled) are necessary

  3. Formulation variability: The bioavailability data applies to standard lotions/creams. Specialized transdermal patches or systems with penetration enhancers represent a different category with higher (though still modest) systemic absorption 3

  4. Marketing claims: Many topical cannabis products make unsubstantiated claims about systemic benefits that are not supported by pharmacokinetic evidence

Bottom Line

For practical clinical purposes, conventional cannabis topical lotions should be considered to have essentially zero systemic bioavailability. The plasma concentrations achieved are orders of magnitude lower than those from oral or inhaled routes and are frequently below quantifiable limits 1. Any therapeutic benefits are likely confined to local tissue effects at the application site.

References

Related Questions

Can I use oral hemp (cannabidiol or tetrahydrocannabinol) products while being treated with methotrexate?
What is the inheritance pattern of a Mendelian autosomal dominant disorder and what are the recommended genetic counseling and testing strategies?
In a 38‑year‑old white male with hypertension on amlodipine 10 mg daily, rosuvastatin 10 mg daily, glipizide extended‑release 5 mg daily with food, hydrochlorothiazide 25 mg daily, losartan potassium 50 mg daily (added one month ago) and metoprolol succinate extended‑release 50 mg daily, with office blood pressure 120/80 mm Hg and home readings 130‑140/80‑90 mm Hg, should I taper and discontinue metoprolol and increase the losartan potassium dose?
Is it safe for a healthy adult to drink a cup of coffee 5–6 hours after taking an immediate‑release 5 mg dose of Adderall (mixed amphetamine salts)?
How should cardioversion be performed in a patient with significant subcutaneous emphysema?
In a 1‑month‑old infant with suspected craniosynostosis, what is the appropriate initial evaluation and management?
In a postmenopausal woman with breakthrough bleeding while on combined estrogen‑progestin hormone replacement therapy, should the progesterone dose be increased to 200 mg, and what is the appropriate management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.